Colorectal cancer (CRC) is still a leading cause of cancer death worldwide. Less than half of
cases are diagnosed when the cancer is locally advanced. CRC is a heterogenous disease …

The Wnt/β-catenin signaling pathway has been implicated as the central mechanism that
drives colorectal carcinogenesis. Its activation is historically due to mutation on APC …

Cancer cells can leverage several cell-intrinsic and-extrinsic mechanisms to escape
immune system recognition. The inherent complexity of the tumor microenvironment, with its …

Adjuvant chemotherapy following surgical intervention remains the primary treatment option
for patients with localized colorectal cancer (CRC). However, a significant proportion of …

Objectives Partial or total resistance to preoperative chemoradiotherapy occurs in more than
half of locally advanced rectal cancer patients. Several novel or repurposed drugs have …

Background KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC),
are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a …

Abstract Background Tumour-infiltrating CD3, CD8 lymphocytes and CD68 macrophages
are associated with favourable prognosis in localised colorectal cancer, but the effect in …

Immune checkpoint inhibitors (ICIs) showed efficacy in metastatic colorectal cancer (mCRC)
with mismatch-repair deficiency or high microsatellite instability (dMMR-MSI-H) …

Aim Stratification of colon cancer (CC) of patients with stage II and III for risk of relapse is still
needed especially to drive adjuvant therapy administration. Our study evaluates the …

Background. Studies have confirmed that Caudal Type Homeobox 2 (CDX2) plays a tumor
suppressor role in colorectal cancer (CRC) and as a prognostic and predictive marker for …